Aprea Therapeutics reported net income of -$3.59M for the quarter ended Jun 2026. This income statement covers 32 quarters of results from Sep 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.07M | 1.09M | 1.10M | 1.17M | 1.73M | 1.66M | 3.73M | 3.73M | 3.74M | 3.74M | 4.20M | 5.43M | 5.43M | 5.48M | 5.51M | 5.75M | 5.98M | 6.54M | 11.98M | 53.48M | ||||||||||||
| Operating items | ||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 6.02M | 4.46M | 4.09M | 6.81M | 1.12M | 0.53M | 1.26M | 2.20M | 2.12M | 2.05M | 1.60M | 2.56M | 2.85M | 2.36M | 2.48M | 1.91M | 1.64M | 1.01M | 1.61M | 2.46M | ||||||||||||
| Selling, General & AdministrativeSG&A | 3.41M | 3.37M | 3.99M | 15.63M | 3.08M | 2.12M | 3.37M | 1.70M | 1.72M | 1.64M | 1.93M | 1.85M | 1.61M | 1.07M | 1.76M | 1.59M | 1.48M | 1.64M | 1.82M | 1.57M | ||||||||||||
| Other Operating ExpensesOther Opex | 76.02M | |||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 9.43M | 7.83M | 8.07M | 98.47M | 4.20M | 2.65M | 4.62M | 3.90M | 3.84M | 3.69M | 3.53M | 4.41M | 4.45M | 3.43M | 4.25M | 3.51M | 3.12M | 2.65M | 3.43M | 4.03M | ||||||||||||
| Operating IncomeOp. Inc | -98.47M | -4.20M | -2.65M | -4.62M | -3.65M | -3.52M | -3.67M | -3.15M | -3.85M | -4.10M | -3.23M | -4.09M | -3.39M | -3.12M | -2.64M | -3.43M | -4.03M | |||||||||||||||
| EBIT | -98.47M | -4.20M | -2.65M | -4.62M | -3.65M | -3.52M | -3.67M | -3.15M | -3.85M | -4.10M | -3.23M | -4.09M | -3.39M | -3.12M | -2.64M | -3.43M | -4.03M | |||||||||||||||
| Non-operating items | ||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -33.00 | 0.00M | 0.00M | 0.05M | 0.15M | 0.24M | 0.26M | 0.34M | 0.32M | 0.31M | 0.28M | 0.38M | 0.35M | 0.27M | 0.20M | 0.18M | 0.15M | 0.12M | 0.13M | 0.36M | ||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.02M | 0.07M | 0.14M | 0.21M | 0.18M | 0.21M | 0.24M | 0.39M | 0.32M | 0.23M | 0.34M | 0.38M | 0.31M | 0.33M | 0.15M | 0.15M | 0.14M | 0.19M | 0.14M | 0.44M | ||||||||||||
| Net income details | ||||||||||||||||||||||||||||||||
| EBT | -98.41M | -4.05M | -2.41M | -4.37M | -3.32M | -3.20M | -3.36M | -2.87M | -3.46M | -3.75M | -2.95M | -3.88M | -3.21M | -2.97M | -2.52M | -3.30M | -3.67M | |||||||||||||||
| Profit After TaxPAT | -9.66M | -7.66M | -7.94M | -98.26M | -4.02M | -2.71M | -4.38M | -3.26M | -3.21M | -3.43M | -2.81M | -3.47M | -3.78M | -2.91M | -3.93M | -3.24M | -2.97M | -2.46M | -3.29M | -3.59M | ||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -98.41M | -4.05M | -2.41M | -4.37M | -3.32M | -3.20M | -3.36M | -2.87M | -3.46M | -3.75M | -2.95M | -3.88M | -3.21M | -2.97M | -2.52M | -3.30M | -3.67M | |||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -98.41M | -4.05M | -2.41M | -4.37M | -3.32M | -3.20M | -3.36M | -2.87M | -3.46M | -3.75M | -2.95M | -3.88M | -3.21M | -2.97M | -2.52M | -3.30M | -3.67M | |||||||||||||||
| Income towards Parent CompanyParent Net Inc | -98.41M | -4.05M | -2.41M | -4.37M | -3.32M | -3.20M | -3.36M | -2.87M | -3.46M | -3.75M | -2.95M | -3.88M | -3.21M | -2.97M | -2.52M | -3.30M | -3.67M | |||||||||||||||
| Net Income towards Common StockholdersNet Income | -98.41M | -4.05M | -2.41M | -4.37M | -3.32M | -3.20M | -3.36M | -2.87M | -3.46M | -3.75M | -2.95M | -3.88M | -3.21M | -2.97M | -2.52M | -3.30M | -3.67M | |||||||||||||||
| Additional items | ||||||||||||||||||||||||||||||||
| EPS (Basic) | -86.85 | -2.34 | -1.45 | -1.34 | -0.89 | -0.86 | -0.93 | -0.68 | -0.58 | -0.63 | -0.54 | -0.65 | -0.53 | -0.47 | -0.39 | -0.22 | -0.07 | |||||||||||||||
| EPS (Diluted) | -86.85 | -2.34 | -1.45 | -1.34 | -0.89 | -0.86 | -0.93 | -0.68 | -0.58 | -0.63 | -0.54 | -0.65 | -0.53 | -0.47 | -0.39 | -0.22 | -0.07 | |||||||||||||||
| Shares Outstanding | 1.06M | 1.06M | 1.10M | 1.13M | 1.73M | 1.66M | 3.26M | 3.73M | 3.74M | 3.62M | 4.20M | 5.94M | 5.94M | 5.51M | 5.99M | 6.08M | 6.37M | 6.54M | 14.69M | 53.48M | ||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.06M | 1.06M | 1.10M | 1.13M | 1.73M | 1.66M | 3.26M | 3.73M | 3.73M | 3.62M | 4.20M | 5.94M | 5.94M | 5.51M | 5.99M | 6.08M | 6.37M | 6.54M | 14.69M | 53.48M | ||||||||||||
| EBITDA | -98.47M | -4.20M | -2.65M | -4.62M | -3.65M | -3.52M | -3.67M | -3.15M | -3.85M | -4.10M | -3.23M | -4.09M | -3.39M | -3.12M | -2.64M | -3.43M | -4.03M |